Danaher Beats Q3 Earnings Estimates but Shares Slide Over 14%

Danaher Corp. posted adjusted earnings of $1.94 per share for its most recent quarter, surpassing the analyst consensus estimate of $1.83. Revenue rose 5.5% year over year to $6.27 billion, outpacing expectations of $6.10 billion. Despite the earnings beat, the stock fell about 14.6% to roughly $172 per share shortly after the results were released.

Benzinga

• Core revenue grew 3% from the prior year, matching the company’s guidance for low-single-digit growth.

Benzinga

• Excluding respiratory-testing revenue, core revenue increased 4.5%.

Benzinga

• Life Sciences revenue climbed 5.5% to $1.88 billion; Diagnostics revenue rose 7% to $2.47 billion.

Benzinga

• Biotechnology revenue grew 4% year over year (2.5% on a core basis) to $1.92 billion.

Benzinga

• The firm lowered its fiscal-2026 core-revenue growth outlook to 3%–4%, down from the prior 3%–6% range, and now expects third-quarter non-GAAP core revenue growth of 2%–3% year over year.

Benzinga

• Adjusted earnings guidance for fiscal 2026 was raised to $8.45–$8.60 per share, aligning with the analyst consensus of $8.45.

Benzinga

CEO Rainer Blair highlighted the strength of the Life Sciences segment, noting that “underlying order trends remained strong” despite timing impacts on bioprocessing projects. The company cited continued end-market recovery and momentum from recent growth initiatives as drivers for its revised outlook. Danaher also signaled a more cautious stance for bioprocessing, now projecting mid-single-digit growth rather than the previously expected high-single-digit expansion.

Benzinga

The earnings beat was insufficient to offset investor concerns about the softened revenue outlook and slower bioprocessing growth expectations, leading to a sharp share-price decline. Analysts may view the lowered 2026 growth range as a signal of heightened market headwinds, particularly from the respiratory-testing segment, while the raised earnings forecast suggests confidence in profitability despite modest top-line growth.

Benzinga

• “While customer project timing impacted bioprocessing revenue, underlying order trends remained strong, and bioprocessing orders grew mid-teens in the quarter,” — Officer Rainer Blair, chief executive

Benzinga